Last reviewed · How we verify

fluticasone furoate, fexofenadine

GlaxoSmithKline · FDA-approved active Small molecule

fluticasone furoate, fexofenadine is a Corticosteroid/antihistamine combination Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Allergic rhinitis, Asthma (in combination therapy). Also known as: fluticasone furoate, fexofenadine.

This combination product delivers a corticosteroid that reduces airway inflammation and an antihistamine that blocks allergic responses to treat allergic rhinitis and asthma.

This combination product delivers a corticosteroid that reduces airway inflammation and an antihistamine that blocks allergic responses to treat allergic rhinitis and asthma. Used for Allergic rhinitis, Asthma (in combination therapy).

At a glance

Generic namefluticasone furoate, fexofenadine
Also known asfluticasone furoate, fexofenadine
SponsorGlaxoSmithKline
Drug classCorticosteroid/antihistamine combination
TargetGlucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
ModalitySmall molecule
Therapeutic areaRespiratory/Allergy
PhaseFDA-approved

Mechanism of action

Fluticasone furoate is an inhaled corticosteroid that binds to glucocorticoid receptors in the airway, suppressing inflammatory cytokine production and reducing mucosal inflammation. Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Together, they address both the inflammatory and allergic components of respiratory allergic disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about fluticasone furoate, fexofenadine

What is fluticasone furoate, fexofenadine?

fluticasone furoate, fexofenadine is a Corticosteroid/antihistamine combination drug developed by GlaxoSmithKline, indicated for Allergic rhinitis, Asthma (in combination therapy).

How does fluticasone furoate, fexofenadine work?

This combination product delivers a corticosteroid that reduces airway inflammation and an antihistamine that blocks allergic responses to treat allergic rhinitis and asthma.

What is fluticasone furoate, fexofenadine used for?

fluticasone furoate, fexofenadine is indicated for Allergic rhinitis, Asthma (in combination therapy).

Who makes fluticasone furoate, fexofenadine?

fluticasone furoate, fexofenadine is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is fluticasone furoate, fexofenadine also known as anything else?

fluticasone furoate, fexofenadine is also known as fluticasone furoate, fexofenadine.

What drug class is fluticasone furoate, fexofenadine in?

fluticasone furoate, fexofenadine belongs to the Corticosteroid/antihistamine combination class. See all Corticosteroid/antihistamine combination drugs at /class/corticosteroid-antihistamine-combination.

What development phase is fluticasone furoate, fexofenadine in?

fluticasone furoate, fexofenadine is FDA-approved (marketed).

What are the side effects of fluticasone furoate, fexofenadine?

Common side effects of fluticasone furoate, fexofenadine include Headache, Pharyngitis, Epistaxis, Dysphonia, Tremor.

What does fluticasone furoate, fexofenadine target?

fluticasone furoate, fexofenadine targets Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine) and is a Corticosteroid/antihistamine combination.

Related